Abstracts tagged "SLE and T-Regulatory Cells"

Abstract Number: 2661 • 2018 ACR/ARHP Annual Meeting
Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus
Meihua Hao¹, Zhaoyun Liang², Xiaona Jing², Chong Gao³, Xiao-Feng Li⁴ and Junwei Chen², ¹The second Hospital of Shanxi Medical University, TaiYuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁴Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose:To observe the clinical efficacy of metformin in the treatment of SLE and regulation of CD4+ Treg and Th17 cells.Methods:Thirty-one patients with SLE, fulfilled the ACR…
Abstract Number: 634 • 2014 ACR/ARHP Annual Meeting
Characterization of CD4⁺ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL)
Harald Leiss¹, Barbara Schwarzecker², Irina Gessl¹, Antonia Puchner¹, Birgit Niederreiter², Carl-Walter Steiner³, Josef Smolen² and Georg H. Stummvoll⁴, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose CD4+ T cells and the Th1 and Th17 subsets in particular play a pivotal role in SLE. Regulatory T cells (Treg) are essential for…
Abstract Number: 633 • 2013 ACR/ARHP Annual Meeting
Reduced PD-1 Signaling Promotes Suppressive Function Of CD4⁺ Regulatory T Cells In Patients With Systemic Lupus Erythematosus
Maida Wong¹, Jennifer M. Grossman², Antonio La Cava³ and Bevra H. Hahn⁴, ¹Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Internal Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Programmed death-1 (PD-1) has been regarded as a negative regulatory signal in T cells. Our laboratory has shown that PD-1 is important in T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].